Table 5 Clinical trials of L2-based vaccines
From: Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded
Vaccine | Class | Phase | Title of trial | Target disease/ HPV type | Administration route | Outcome measures | NCT | Sponsor | Status |
|---|---|---|---|---|---|---|---|---|---|
Adeno-associated VLPs (AAVLP) | VLP-based vaccine | I | A study of safety, tolerability, and immunogenicity of HPV-L2 vaccine in healthy adult male and female subjects | Antibodies against HPV-6/11/16/18 | Intramuscular (IM) | 1. Percentage of local/ general symptoms 2. Percentage of adverse events 3. Vital signs | NCT03929172 | 2A Pharma AB | Completed/ Last updated in 2020 |